Please login to the form below
ipilimumab
This page shows the latest ipilimumab news and features for those working in and with pharma, biotech and healthcare.
BMS CEO tackles investor ‘frustrations’ on immuno-oncology
BMS was the pathfinder for the checkpoint inhibitor market with its CTLA4 inhibitor Yervoy (ipilimumab) and PD-1 blocker Opdivo (nivolumab), However, it has since lost ground to rival Merck
Latest news
-
Merck’s Bavencio joins first-line kidney cancer face-off
Both combinations could challenge the position of Bristol-Myers Squibb’s Opdivo (nivolumab) and Yervoy (ipilimumab), which has started to replace Sutent and other TKIs like Exelixis’Cabometyx (cabozantinib) as the
-
Keytruda hits survival targets in first-line kidney cancer
Bristol-Myers Squibb’s cancer immunotherapy pairing of PD-1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab) was approved earlier this year as first-line treatment for RCC, but only
-
BMS finds a new immunotherapy partner with $12m Compugen deal
In February, it signed a huge $3.6bn deal to pair Nektar's NKTR-214 with Opdivo and its CTLA4 inhibitor Yervoy (ipilimumab) in a host of tumour types.
-
Checkpoint inhibitor scientists win Nobel Prize
at the heart of research into CTLA4 which led to the development of inhibitors such as BMS’ Yervoy (ipilimumab) and various late-stage clinical candidates.
-
NICE turns down Opdivo for adjuvant melanoma therapy
Opdivo was approved for adjuvant treatment of melanoma on the back of data from the CheckMate-238 trial showing that it was superior to BMS’CTLA4 inhibitor Yervoy (ipilimumab) in reducing
More from news
Approximately 9 fully matching, plus 157 partially matching documents found.
Latest Intelligence
-
Cancer immunotherapy: What's on the horizon?
drug Yervoy (ipilimumab) in an early-stage trial.
-
Pharma deals in February 2015
As well as the already marketed Yervoy (ipilimumab) and recently FDA approved Opdivo (nivolumab), BMS has four additional immuno-oncology drugs in clinical trial.
-
Pharma deals during July 2014
In this collaboration the focus is Opdivo (nivolumab), an anti-PD-1 antibody that is approved in Japan for unresectable melanoma, and Yervoy (ipilimumab), an anti-CTLA-4 antibody that is
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
BMS appoints oncology development head
On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab).
-
CytomX appoints Rachel Humphrey chief medical officer
drug Yervoy (ipilimumab).
-
Jonathan Dickinson joins Ariad from BMS
population. He has previous experience in the commercialisation of cancer drugs, serving for the past three years as BMS' European brand lead for Yervoy (ipilimumab).
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Immunotherapy in oncology
This was the case with the development of ipilimumab (Yervoy) where response-based endpoints (overall response rate [ORR] and progression free survival [PFS]) were the primary endpoints of the phase II ... This led to a changing of the primary clinical
-
Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships
Yervoy (ipilimumab, Bristol-Myers Squibb) is a first-generation agent which was approved by the FDA in 2011 for advanced melanoma.
-
ASCO 2015: What you missed in Chicago
Bristol-Myers-Squibb redefines Melanoma treatment standards. In terms of winners here, BMS is likely to redefine the standard of care in Melanoma with the Opdivo/Yervoy (ipilimumab) combination. ... Patel SP et al Mol Cancer Ther 2015[2] Combined
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Featured jobs
- Events Manager – Med Comms – Surrey
-
Salary TBC
-
Account Director
-
£48, 000 - £60, 000
- Digital Manager, London – Healthcare Brandcomms, Medcomms, PR
-
Excellent package
- Senior Account Managers - Oxfordshire
-
Attractive salary and benefits package offered
- Director, Market Access / HEOR - North-West
-
Negotiable
- Account Manager, Healthcare Public Affairs
-
£32, 000 – £40, 000 benefits
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Senior Systematic Review Analyst - Oxford
-
Negotiable
-
Associate Director
-
£75, 000-90, 000
- Programme Director, Healthcare PR, Highly competitive package
-
Highly Competitive package
- Scientific Director / Editorial Team Leader
-
Great salary and benefits
-
Senior Medical Writer
-
Great salary and benefits
-
Account Manager / Account Director
-
Competative
- Senior Account Executive, London, Medical Communications
-
Excellent package
-
Medical/ Scientific Director
-
Salary TBC
- Account Manager / Senior Account Manager
-
35, 000-40, 000
Subscribe to our email news alerts
- Behaviour change: what is the buzz all about?
- Worldwide Clear Aligner Market to grow at a CAGR of 16.15% By 2023
- Worldwide Prenatal and New-born Genetic Testing Market Set to Register 11.9% CAGR During 2018-2024
- Medical Biomimetics Market soaring at 5.5% CAGR to Hit USD 34.4 Billion By 2024
- Medical Marijuana Market to Soar at 36% CAGR to 2024
- Worldwide Medical Ultrasound Imaging Equipment Market to Witness Robust Expansion Throughout the Forecast Period 2018 – 2023
PMHub
PRMA Consulting Ltd
PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...
Latest intelligence
- OUTiCO win Best in UK Pharmaceutical Outsourcing award
- The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
- Artificial Intelligence in Healthcare
- Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
- World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
- Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
Quick links
Infographics
